Brief: Context Therapeutics® Amends Cash Guidance, Extends Runway Into Q1 2024

Context Therapeutics

27/09/2022 12:51

Sept 27 (Reuters) - Context Therapeutics Inc  CNTX.O :
    * CONTEXT THERAPEUTICS® AMENDS CASH GUIDANCE, EXTENDS RUNWAY
INTO
Q1 2024
    * CONTEXT THERAPEUTICS - PLANS TO DEFER NONCRITICAL RESEARCH
AND
DEVELOPMENT ACTIVITIES, REDUCE FUTURE OVERHEAD, INFRASTRUCTURE
EXPENDITURES
    * CONTEXT THERAPEUTICS - PRIORITIZING ONAPRISTONE EXTENDED
RELEASE
(ONA-XR) ELONA PHASE 1B/2 CLINICAL TRIAL, CLAUDIN 6 (CLDN6)
PROGRAM
    * CONTEXT THERAPEUTICS - ANTICIPATES NOMINATION OF CLDN6XCD3
BISPECIFIC MONOCLONAL ANTIBODY DEVELOPMENT CANDIDATE WITH
INTEGRAL MOLECULAR IN Q4 2022
    * CONTEXT THERAPEUTICS - IND SUBMISSION FOR CLDN6 IS PLANNED
IN Q1
2024
    * CONTEXT THERAPEUTICS - REMAINS ON TRACK TO INITIATE ELONA
CLINICAL TRIAL IN Q4 2022 AND TO REPORT PHASE 1B DATA IN Q4 2023
    * CONTEXT THERAPEUTICS - ANTICIPATES SHARING PRELIMINARY
DATA FROM
PHASE 2 CLINICAL TRIALS IN GRANULOSA CELL TUMORS, ENDOMETRIAL
CANCER IN NOV 2022
    * CONTEXT THERAPEUTICS - ANTICIPATES SHARING PRELIMINARY
DATA FROM
PHASE 2 CLINICAL TRIAL IN BREAST CANCER IN DEC 2022
    * CONTEXT THERAPEUTICS - WILL CONTINUE TO PROVIDE ACCESS TO
ONA-XR
THROUGH COMPANY'S ONGOING INVESTIGATOR-SPONSORED TRIALS

Source text for Eikon:  ID:nGNX4HNZtz 
Further company coverage:  CNTX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))